Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 39325506.
- Also identified by DOI 10.1093/cid/ciae465 and PMC identifier 11797383.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
For COVAIL recipients of a coronavirus disease 2019 (COVID-19) Sanofi booster vaccine, neutralizing antibody titers were assessed as a correlate of risk (CoR) of COVID-19. Peak and exposure-proximal titers were inverse CoRs with covariate-adjusted hazard ratios (95% confidence intervals) 0.30 (0.11, 0.78) and 0.25 (0.07, 0.85) per 10-fold increase in weighted average titer.
Medical subject headings
- Antibodies, Neutralizing
- Antibodies, Viral
- COVID-19
- COVID-19 Vaccines